Butaney M, Satkunasivam R, Goldberg H, et al. - As for many advanced malignancies, immunotherapy (IO) has become standard of care (SOC), researchers here investigated the demographic factors that could be associated with response to IO, compared with SOC systemic therapy, using stratified meta-analysis. Conducting a systematic review of MEDLINE, PubMed, Embase, and Scopus from inception to October 2, 2018, they identified 21 eligible randomized controlled trials; these included 20 stratified by age, 17 by performance status (PS), and 4 by race. They identified no significant differences in IO efficacy according to patient age, PS or race when examined overall survival using stratified meta-analysis.